Skip to main content

Medications for Non-Small Cell Lung Cancer

The medications listed below are related to or used in the treatment of this condition.

Filter
Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
pembrolizumab 4.4 100 reviews for pembrolizumab to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
pembrolizumab systemic
Brand name:
Keytruda
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Keytruda 4.2 96 reviews for Keytruda to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
pembrolizumab systemic
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
nivolumab 5.2 47 reviews for nivolumab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
nivolumab systemic
Brand name:
Opdivo
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
erlotinib 8.5 40 reviews for erlotinib to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
erlotinib systemic
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
osimertinib 7.3 37 reviews for osimertinib to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
osimertinib systemic
Brand name:
Tagrisso
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Tagrisso 7.1 34 reviews for Tagrisso to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
osimertinib systemic
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Opdivo 4.9 32 reviews for Opdivo to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
nivolumab systemic
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
gefitinib 8.9 8 reviews for gefitinib to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
gefitinib systemic
Brand name:
Iressa
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Iressa 8.9 8 reviews for Iressa to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
gefitinib systemic
Drug class:
EGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
crizotinib 7.8 7 reviews for crizotinib to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
crizotinib systemic
Brand name:
Xalkori
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Retevmo 10 4 reviews for Retevmo to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
selpercatinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
selpercatinib 10 4 reviews for selpercatinib to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
selpercatinib systemic
Brand name:
Retevmo
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Xalkori 9.3 4 reviews for Xalkori to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
crizotinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
afatinib 7.7 3 reviews for afatinib to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
afatinib systemic
Brand name:
Gilotrif
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Enhertu 8.3 3 reviews for Enhertu to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
fam-trastuzumab deruxtecan systemic
Drug class:
HER2 inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
fam-trastuzumab deruxtecan 8.3 3 reviews for fam-trastuzumab deruxtecan to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
fam-trastuzumab deruxtecan systemic
Brand name:
Enhertu
Drug class:
HER2 inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Alecensa 9.5 2 reviews for Alecensa to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
alectinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
alectinib 9.5 2 reviews for alectinib to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
alectinib systemic
Brand name:
Alecensa
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
amivantamab 9.0 2 reviews for amivantamab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
amivantamab systemic
Brand name:
Rybrevant
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
atezolizumab 8.5 2 reviews for atezolizumab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
atezolizumab systemic
Brand name:
Tecentriq
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
durvalumab 6.0 2 reviews for durvalumab to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
durvalumab systemic
Brand name:
Imfinzi
Drug class:
anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
gemcitabine 8.5 2 reviews for gemcitabine to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
gemcitabine systemic
Brand names:
Gemzar, Infugem
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
pemetrexed 9.0 2 reviews for pemetrexed to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
pemetrexed systemic
Brand names:
Alimta, Pemfexy, Pemrydi RTU
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Rybrevant 9.0 2 reviews for Rybrevant to treat Non-Small Cell Lung Cancer
Rx N
Generic name:
amivantamab systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Abraxane 1.0 1 review for Abraxane to treat Non-Small Cell Lung Cancer
Rx D N
Generic name:
paclitaxel protein-bound systemic
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects

Frequently asked questions

View more FAQ

Learn more about Non-Small Cell Lung Cancer

Care guides

Symptoms and treatments

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.